作者： sarah

TOKYO, Sept 26, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has completed production of the core stage of the 50th and final H-IIA launch vehicle at its Tobishima Plant in the Nagoya Aerospace Systems Works in Aichi Prefecture. The core stage is scheduled for shipment to the Tanegashima Space Center in Kagoshima Prefecture.Since the flight of the first vehicle in 2001, the H-IIA has delivered various payloads to space as Japan's flagship launch vehicle. A total of 48 vehicles have been launched to date, with a launch success rate of around 98%. The H-IIA launch vehicle will be retired following the launch of vehicle No. 50, and succeeded by the new H3 launch vehicle.MHI began providing launch services in 2007 that coordinate the entire process from launch vehicle manufacturing to execution of the launch campaign, and in 2013 added the H-IIB to its lineup.(Note) Going forward, MHI will continue contributing to the development of autonomous space transportation in Japan.The H-IIB launch vehicle was Japan's flagship launch vehicle, in operation from September 2009 to May 2020. It made a total of nine flights as a heavy-lift vehicle carrying necessary supplies to the International Space Station (ISS). (Launch success rate:100%)About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Sept 25, 2024 - (JCN Newswire via SeaPRwire.com) - Osaka Gas Co., Ltd. (Osaka Gas) and Mitsubishi Heavy Industries, Ltd. (MHI) today announced their agreement to implement CO2NNEX®, the city gas industry's first digital platform for visualizing traded carbon dioxide (CO2) at Expo 2025 Osaka, Kansai, Japan (the Expo). In addition to using this platform for e-methane, Osaka Gas and MHI will also pursue the possibility of expanding its application to carbon recycles fuel (e-fuel, SAF, Green LPG) in the future.On April 1, 2024, the private sector began to use clean gas certificates, which certifies the environmental value(Note1) of e-methane and biogas. As the same operation as non-fossil fuel certificates for electricity is proceeding for gas, a system is required to manage transactions and transfers of the environmental value of clean gas certificates. CO2NNEX® will be equipped with functions to manage e-methane attribute data (production volume, amount of CO2 and H2 used as raw materials, etc.), which is necessary for the social implementation of e-methane, and functions to manage and transfer the environmental value created by e-methane and biogas. The Japan Gas Association has indicated that further guidance will be provided to companies regarding the functions installed in this platform and proceed with implementation. (Figure 1)Figure 1: e-methane-related functions of CO2NNEXDuring the Expo, Osaka Gas will provide the guesthouses and other facilities with on-site-produced e-methane, natural gas adds a value of environmental value of e-methane or biogas. The platform will manage attributed data and the environmental value created during the production and use demonstration(Note2) of e-methane at the Expo site, as well as to transfer the environmental value of e-methane and biogas produced by city gas companies around Japan to Osaka Gas natural gas supplied to the Expo site, further contributing to the carbon neutrality of the Expo 2025. (Figure 2)Figure 2: Image of CO2NNEX implementation at the ExpoOsaka Gas aims to introduce e-methane, which accounts for 1% of the city gas it delivers, by 2030. As the value of e-methane and environmental value transactions will increase significantly in the future, MHI anticipates expanding the use of this platform, which can manage e-methane attribute data and manage and transfer environmental value. Introduction to the carbon recycling fuels other than e-methane (e-fuel, SAF, and Green LPG) is also under consideration, and as value of trade increase, a system for managing attribute data and managing and transferring environmental value is expected to become necessary. In addition to CCU(Note3) (CO2 utilization), such as carbon recycling fuel, CCS(Note4) (storage of CO2) is expected to be more widely used in the future and MHI is actively exploring the potential of expanding the application of the platform to manage CO2 distribution. Furthermore, it is also expected to expand to introduce this platform to Asian countries that are considering the introduction of e-methane and SAF. (Figure 3)Figure 3: Future potential expansion of the CO2NNEX platformThrough the development and commercialization of CO2NNEX®, Osaka Gas and MHI aim to promote the widespread usage of e-methane, contributing to achieving a carbon-neutral society.(1) This environmental value refers to the net zero emissions of CO2 from utilizing (combusting) e-methane, which is achieved through the carbon recycling by producing e-methane from captured CO2 emitted into or already existing in the atmosphere.(2) This e-methane production and utilization refers to the project of hydrogen supply chain development and demonstration in urban areas using e-methane produced from green hydrogen and biogas derived from kitchen waste. The project has been adopted as the FY2022 model development and demonstration project for the cost reduction in hydrogen supply utilizing the existing infrastructure.(3) CCU refers to Carbon dioxide Capture and Utilization.(4) CCS refers to Carbon dioxide Capture and Storage.About Osaka GasOsaka Gas aims to achieve net-zero emissions across its group under the Carbon Neutral Vision the company announced in 2021. Osaka Gas is developing technologies and services that drive the decarbonization of society. As a company serving customers for their life and business advancement, Osaka Gas is actively addressing climate change and other social challenges.About MHIMHI Group is actively involved in programs targeting the realization of a carbon neutral society. Building a CO2 ecosystem is central to its energy transition initiatives. As a global leader in CCUS, the company aims to accelerate this ecosystem development by seeking widespread adoption of related hardware as well as the CO2NNEX® digital platform.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.

LONDON, Sept 25, 2024 - (JCN Newswire via SeaPRwire.com) - Hitachi Rail’s digital asset management suite – powered by NVIDIA AI technology – launches today and is transforming the way transport operators run and maintain railways.The HMAX (Hyper Mobility Asset Expert) suite is an all-in-one digital asset management platform that providestransport operators with an array of AI-enhanced digital solutions to optimize trains, signaling and infrastructure management.Hitachi’s digital tools already use digital sensors to remotely monitor the health of assets and improve their performance. The HMAX platform offers a leap forward as live data collection is combined with powerful AI technologyto dramatically enhance the speed, ease and depth of analysis. Using the powerful insights offered by HMAX, operators can now more accurately predict, optimize and transform their services.Hitachi Rail is leveraging NVIDIA’s industrial AI platform and software tools, and Hitachi Digital’s AI Centre ofExcellence and software engineering expertise, to offer operators more advanced, innovative solutions. The HMAX digital platform’s “edge to cloud” architecture means Hitachi Rail’s customers will be able to remotely access theseinnovations all through a single portal, as well as at operational centers. The solutions are part of Hitachi’s vision to bring the power of AI into the world of Operational Technology, equipping frontline workers, engineers and operators with the powerful benefits of AI.The collaboration with NVIDIA incorporates the industrial-grade NVIDIA IGX platform with NVIDIA Holoscan sensor processing platform, allowing volumes of data to be processed at the ‘edge’ (on the trains or infrastructure) in real time, with only relevant information sent back to the operational control centers. This enables an unprecedented improvement in the speed that actionable insights reach transport operators, as previously it could take up to ten days for data to be processed in maintenance locations.Speaking at the company’s showcase at InnoTrans, Berlin, Hitachi Rail CEO, Giuseppe Marino, said:“At Hitachi Rail, we believe AI has immediate and very impactful applications that will make the railways run more efficiently. Our AI-enabled digital asset management is a solution for optimizing customers’ rail services and enhancing railway performance. We are delighted by our collaboration with NVIDIA, which will combine the power ofAI with advanced Hitachi Rail technologies to enhance railway outcomes for operators.”Yogesh Agrawal, Vice President of Data Center Business at NVIDIA, said:“The railway, a system strengthened by the first industrial revolution, is at the forefront of the latest paradigm shift toward a digital transformation with AI. Hitachi Rail’s HMAX solution, powered by NVIDIA IGX and Holoscan, will offerthe real-time computing capabilities needed to help boost the manageability, safety and availability of rail systems to meet the needs of operators and today’s travelers.”About NVIDIA IGXNVIDIA IGX is an edge AI platform that combines enterprise-level hardware, software and support. It is purpose-built for industrial and medical environments, delivering powerful AI compute, high-bandwidth sensor processing, enterprise security and functional safety.The Hitachi Digital AI Center of Excellence (COE) serves as a hub for Hitachi and its customers – providing a common AI infrastructure, governance, and technical and operational expertise. The COE’s knowledge and resourceswill be augmented by the NVIDIA collaboration.About Hitachi RailHitachi Rail is committed to driving the sustainable mobility transition and has a clear focus on partnering with customers to rethink mobility. Its mission is to help every passenger, customer and community enjoy the benefits of more connected, seamless and sustainable transport.With revenues of over €7bn and 24,000 employees across more than 50 countries, Hitachi Rail is a trusted partnerto the world’s best transport organisations. The company's reach is global, but the business is local - with successbuilt on developing local talent and investing in people and communities.Its international capabilities and expertise span every part of the urban, mainline and freight rail ecosystems – fromhigh quality manufacturing and maintenance of rolling stock to secure digital signaling, smart operations and payment systems. Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Sept 24, 2024 - (JCN Newswire via SeaPRwire.com) - Honda announced that it will participate in JAPAN MOBILITY SHOW BIZWEEK 2024 to be held at Makuhari Messe in Chiba Prefecture, Japan from October 15 (Tuesday) to 18 (Friday), 2024.Honda boothJAPAN MOBILITY SHOW BIZWEEK 2024 will be held as an event to promote new business co-creation by strengthening collaboration between companies. The Honda booth aims to communicate with participating and visiting companies by showcasing UNI-ONE capable of DX coordination such as augmented reality (AR) and virtual reality (VR), and seek partners interested in selling / handling “SmaChari,” a service that converts conventional bicycles to be electrically assisted and connected by attaching an electric power assist unit and connecting a smartphone app.Honda will also introduce IGNITION, a new business creation program aimed at solving social issues, and Honda Xcelerator Ventures, an open innovation program promoting collaboration between startup companies and Honda.Main exhibitsUNI-ONE Hands-Free Personal MobilityUNI-ONE is a seated personal mobility that allows the user to use both hands freely. Through Honda’s balance control technology developed from robotics research and the unique Honda Omni Traction Drive System, UNI-ONE users can walk at a height close to pedestrians while both hands are free, enabling communication with surrounding people while moving. UNI-ONE assists the mobility of various people, and creates the joy of freedom of mobility, enhancing the user’s desire to move. By adding a DX aspect to the UNI-ONE, Honda will search for, and communicate with, partners to provide a new future mobility experience.SmaChariSmaChari consists of a smartphone application and an electric power assist unit attached to a bicycle. It is the first of its kind in Japan(1) and enables various types of bicycles to be electrically assisted and connected through output control technology that complies with regulations. In addition, using a smartphone application, users can access a variety of functions and information utilizing the connected functionality, such as personalized assist output optimization, fault detection, ride data management, location information sharing, and owner information management.Honda will provide SmaChari smartphone apps to customers, as well as various licenses to companies that manufacture and sell SmaChari-equipped bicycles, including technology related to the control software of the electric power-assist unit, and a paid connected platform to operate and manage SmaChari.Honda aims to equip SmaChari on a wide range of bicycles in the future, and will continue to evolve the system.(1) As of March 2023 (Honda research)IGNITIONIGNITION is a new business creation program started by Honda R&D Co., Ltd. in 2017, which gives shape to the creative technologies, ideas, and designs of employees, leading to the solution of social issues and the creation of new values. In 2021, the program was expanded to cover all of Honda.Since then, IGNITION expanded beyond Honda, and by combining ideas from outside the company with Honda’s technologies and expertise, the program aimed to further solve social issues and create new values. In 2024, Honda has selected three themes from applications to a public invitation, to help solve the social issues raised in the selected themes.Reference: Selected themesMobility that enables rapid standing-up and standing mobility, for people with lower limb motor function disabilities who have difficulty standing up and walking long distances (Yosuke Eguchi, Qolo Co., Ltd. CEO)Walking rehabilitation system for stroke patients that is easy to use and fun for rehabilitation (Prof. Yano, Virtual Reality Laboratory, University of Tsukuba)“Robiotope” aiming to protect nature by fostering a sense of attachment to nature and environmental awareness, through growing plants with robots in a biotope of their choice (Toki Kageyama, National Institute of Technology, Numazu National College of Technology)Honda Xcelerator VenturesHonda Xcelerator Ventures is Honda’s open innovation program that promotes collaboration between Honda and startup companies. Through this program, Honda is investing in and collaborating with a number of global venture companies with advanced technologies in Japan, North America, Europe, Israel, among other regions.In April 2023, Honda established Honda Innovations Co., Ltd. in Japan to conduct global corporate venturing, and established a system for speedy investment and collaboration with startups that possess innovative technologies and ideas in conjunction with Honda’s corporate strategy. Honda has allocated an annual budget on the scale of 10 billion yen to invest in startups and other companies with promising cutting-edge technologies and business models in areas such as AI, synthetic fuels, battery recycling, and nuclear fusion power generation, aiming to broaden the scope of its technologies and businesses in the future.Helm.ai (U.S.): AI image recognition technology based on unsupervised learningEmulsion Flow Technologies Ltd. (Japan): efficient extraction of rare metals from batteriesnT-Tao (Israel): Developing small modular fusion power generationIn addition, the Japan Automobile Manufacturers Association (JAMA) will exhibit vehicles such as the CR-V e:FCEV fuel cell vehicle and the EM1 e: electric personal commuter motorcycle.Honda Exhibits  Honda boothExhibited modelsUNI-ONERAIL DISC-e with SmaChariMessageIGNITIONHonda Xcelerator VenturesJAMA’s member automobile manufacturers boothExhibited models(All production models)CR-V e:FCEVEM1 e:Honda Power Pack e:Honda Power Pack Exchanger e:JAPAN MOBILITY SHOW BIZWEEK 2024 OverviewTitleJAPAN MOBILITY SHOW BIZWEEK 2024DatesOctober 15 (Tuesday) - 18 (Friday), 2024Times10:00～17:00VenueMakuhari Messe (International Exhibition Hall 1)Address2-1 Nakase, Mihama-ku, Chiba-shi, ChibaAdmissionFree (online registration required)OrganizerJapan Automobile Manufacturers Association, Inc. (JAMA)SponsorJapan Auto Parts Industries Association (JAPIA)Websitehttps://www.japan-mobility-show.com/en/ Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Sept 24, 2024 - (JCN Newswire via SeaPRwire.com) - Tosha Schareina (Spain, age 29), riding the CR ELECTRIC PROTO motocross racer for Honda Racing Corporation (HRC) factory team(1) Team HRC, was crowned champion in the men’s category in the final round of the FIM(2) E-Xplorer World Cup, an international electric all-terrain motorcycle racing series, held in Switzerland on September 21 and 22. Francesca Nocera (Italy, age 30) finished second in the women’s category, and Team HRC was second overall in the team category.HRC which announced its full participation from 2024 in the E-Xplorer World Cup, which started in 2023, has won the championship in its first year.Honda is committed to the electrification of motorcycles as the cornerstone of its environmental strategy, aiming to achieve carbon neutrality in all of its products and corporate activities by 2050 and in all of its motorcycle products by the 2040s. In the area of motorsports, the introduction of electric technology in competition has allowed Honda to accumulate know-how and knowledge, and has become a milestone in the evolution of Honda’s technology.In the 2024 season, Honda will accelerate its electrification efforts by introducing the newly developed RTL ELECTRIC in the MFJ(3) All Japan Trial Championship.Koji Watanabe, President of Honda Racing Corporation“I would like to extend my heartfelt congratulations to Tosha Schareina for winning the championship in the FIM E-Xplorer World Cup men’s category. He showed consistent and strong performance in the completely new category of electric off-road racing. I would also like to pay tribute to Francesca Nocera, who pushed hard until the end despite of pain from her fall in practice. Last but not least, I would like to thank the team staff who helped us win the championship, as well as our sponsors and all the off-road racing fans who support our racing activities.”Tosha Schareina | Team HRC“I’m absolutely thrilled to have secured the victory as the men’s World Champion in E-Xplorer. The team should be proud of all the hard work they’ve put in this season. I want to extend my congratulations to Francesca for never giving up and finishing the race after her fall on Friday. The CR ELECTRIC PROTO has performed incredibly throughout the entire year, and the team has given their all—they should be proud.”(1) Factory team: Racing team managed by the bike manufacturer. For Honda, Honda Racing Corporation (HRC) manages its factory teams.(2) FIM: Fédération Internationale de Motocyclisme(3) MFJ: Motorcycle Federation of JapanAbout Tosha SchareinaCareer highlights:2021Dakar Rally 2021: 13th2023Dakar Rally 2023: 13th2024Dakar Rally 2024E-Xplorer World Cup Champion (Men’s category)About E-XplorerThe FIM E-Xplorer World Cup is an international electric all-terrain motorcycle racing series that started in 2023, in which mixed-gender teams compete. This season’s competition consisted of qualifying and three heat races for the men’s and women’s categories to determine the top 3 teams.This year’s E-Xplorer World Cup was contested over four rounds, beginning at the Expo’70 Commemorative Park (Festival Square) in Suita City, Osaka Prefecture, on February 16-17, before moving to Norway (Round 2) and Switzerland (Rounds 3 and 4).  Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Sept 24, 2024 - (JCN Newswire via SeaPRwire.com) - Mazda Motor Corporation will open a new R&D office in the cosmopolitan Azabudai Hills (Azabudai, Minato-ku, Tokyo) in early summer 2025, an area projected to see continuous development.Mazda has set out its 2030 VISION "to be a car-loving company that creates moving experiences through the 'joy of driving'" and aspires to an ideal where everyone connected to the Mazda brand feels mentally refreshed, physically invigorated, and optimistic about each day.As advanced technologies such as generative AI gain widespread use, it is crucial to continue innovating software technologies alongside traditional hardware to deliver vibrant, engaging experiences to our customers through their cars. The new R&D office is expected to house development facilities, particularly in software, demonstrating Mazda's goal to become a dynamic workplace of choice for software engineers. It will also function as a hub for collaborative innovation, fostering partnerships with universities, companies, and research institutions in the Tokyo metropolitan area.Based on the belief that our people are our most valuable resource, Mazda is promoting initiatives, like this new R&D office, to maximize the contributions of its personnel, including corporate culture reforms, improvements to HR systems, and the establishment of value-creation platforms.In our aspiration to create a comfortable working environment, the new R&D office will feature an open workspace and be equipped with the latest technology. Further details regarding the specific floor area and facilities will be announced in due course.Azabudai Hills, the location for Mazda's new R&D officeTrue to Mazda's "human-centered" philosophy and commitment to the pursuit of a comfortable and rewarding work environment, we endeavor to create an exemplary company where every employee feels the pride and energy to work with enthusiasm. Copyright 2024 JCN Newswire via SeaPRwire.com.

Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing authorization approval for amyotrophic lateral sclerosis (ALS) treatment “Rozebalamin® for Injection 25 mg” (mecobalamin) in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. In May 2022, it received orphan drug designation, and a new drug application was submitted in January 2024, leading to this approval.This approval is based on the results of JETALS (The Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS), multicenter, placebo-controlled, double-blind, randomized Phase III clinical trial in 130 patients with ALS, that was conducted as an investigator-initiated trial by a research team with Extraordinary Professor Ryuji Kaji (Principal Investigator), Tokushima University, and Professor Yuishin Izumi (Coordinating Investigator), the Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, and Professor Satoshi Kuwabara (Coordinating Investigator), the Department of Neurology, Chiba University Graduate School of Medicine.In JETALS, the mecobalamin 50mg group showed a statistically significant slowing of progression compared to the placebo group in the change in total score from the end of the observation period to week 16 of the treatment period in the primary endpoint, the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) (slowing decline by approximately 43%, p=0.01).1 The adverse drug reaction incidence rates were 1.6% in the placebo group and 7.7% in the mecobalamin 50 mg group. Adverse reactions observed in the mecobalamin 50 mg group included constipation, injection site pain, fever, electrocardiogram QT prolongation and rash, each occurring in 1.5% of patients.2ALS is an intractable, progressive, neurodegenerative disease that results in severe muscle atrophy and weakness in the muscles due to motor neuron dysfunction. As the main cause of death is respiratory failure due to paralysis of the respiratory muscles, without the use of an artificial respirator, death occurs within approximately 2 to 5 years from the onset of the disease.3 The number of patients in Japan is estimated to be approximately 10,000. 3 Currently, there is no curative treatment established for ALS, and since there are only limited number of medicines approved in Japan and abroad, this is a disease with significant unmet medical needs.Eisai considers neurology a therapeutic area of focus. As a human healthcare company, Eisai is committed to further addressing the diverse needs of, and increasing the benefits of, patients and their families by providing Rozebalamin as a new treatment option for ALS patients.1. Product Outline1) Product nameRozebalamin® for Injection 25 mg2) Generic nameMecobalamin3) Indication for useSlowing progression of functional impairment in amyotrophic lateral sclerosis4) Dosage and administrationThe usual dose of mecobalamin in adults is 50 mg a day, twice a week, injected intramuscularly.About Rozebalamin (generic name: mecobalamin, development code: E0302)Mecobalamin is approved and marketed as Methycobal®, a 500 µg injection of mecobalamin indicated for the treatment of peripheral neuropathies and megaloblastic anemia caused by vitamin B12 deficiency. Methycobal is also approved as a tablet formulation (250 µg and 500 µg) as well as a fine granule formulation (0.1%) indicated for the treatment of peripheral neuropathies. While the mechanism of action of mecobalamin against amyotrophic lateral sclerosis (ALS) is not known, it has been suggested in non-clinical research that mecobalamin may have efficacy through a neuroprotective effect and regeneration of nerve axons. Since the 1990s, clinical research has been carried out on ultrahigh-dose mecobalamin in ALS by a study group on neurodegenerative disease, funded through the Ministry of Health, Labour and Welfare's Specified Disease Treatment Research Program. Short- and long-term trials of intramuscular injection of mecobalamin at 25 mg and 50 mg per day, which is respectively 50 and 100 times the approved dosage of Methycobal, suggested that ultrahigh-dose mecobalamin could have a clinical effect in ALS, and Eisai then conducted the Phase II/III clinical trial (Study 761) from 2006. Eisai submitted a new drug application for ultrahigh-dose mecobalamin as treatment for ALS in May 2015 but withdrew the application in March 2016 after the Pharmaceuticals and Medical Devices Agency (PMDA) indicated that additional clinical trials were necessary.After obtaining favorable results in the investigator-initiated Phase III trial JETALS, and following consultation with Tokushima University, Eisai submitted a new drug application for the treatment of ALS in Japan in January 2024, leading to this approval.About Japan Early-stage Trial of Ultrahigh-Dose Methylcobalamin for ALS (JETALS)The Japan Early-stage Trial of Ultrahigh-Dose Methylcobalamin for ALS (JETALS) is an investigator-initiated study conducted as a multicenter, placebo-controlled, double-blind, randomized Phase III clinical trial to verify the efficacy and safety of high-dose methylcobalamin (mecobalamin) in patients with amyotrophic lateral sclerosis (ALS).1Mecobalamin 50 mg or placebo was administered intramuscularly twice weekly for 16 weeks to 130 ALS patients who had suffered from ALS for less than one year, were classified as “definite”, “probable”, or “probable- laboratory supported” according to the Updated Awaji Criteria, had an ALS severity rating of grade 1 or 2, had a decrease of 1 or 2 points in the total score on the Revised ALS Functional Rating Scale-Revised (ALSFRS-R) 12 weeks prior to administration, and had a forced vital capacity (%FVC) of more than 60%.2The primary endpoint was the change in ALSFRS-R total score from the end of the observation period to week 16 of the treatment period. The change was -2.7 [95% confidence interval (CI): -3.9, -1.5] in the mecobalamin50 mg group and -4.6 [95% CI: -5.8, -3.4] in the placebo group, with a difference in change of 2.0 (95% CI: 0.4, 3.5; p=0.012), verifying the superiority of mecobalamin 50 mg over placebo.2 The adverse drug reaction incidence rate was 1.6% (1/64 cases) in the placebo group and 7.7% (5/65 cases) in the mecobalamin 50 mg group. Adverse drug reactions observed in the mecobalamin 50 mg group were constipation, injection site pain, fever, electrocardiogram QT prolongation, and rash, occurring in 1.5% (1/65 cases) each.2(1) Oki R, et al. Efficacy and safety of ultrahigh-dose methylcobalamin in early-stage amyotrophic lateral sclerosis a randomized clinical trial. JAMA Neurol. 2022;79(6):575-583.(2) Information stated in the package insert.(3) Japan Intractable Diseases Information Center, Amyotrophic lateral sclerosis (ALS), Designated intractable disease (2). https://www.nanbyou.or.jp/entry/52. Last accessed: September 2024. (Japanese only)Media Inquiries:Public Relations Department, Eisai Co., Ltd.+81-(0)3-3817-5120 Copyright 2024 JCN Newswire via SeaPRwire.com.

KYOTO, Japan, September 24, 2024 - (JCN Newswire via SeaPRwire.com) - Valuufy, a pioneering force in sustainability assessment, announces its CEO Kyle Barnes will present at the prestigious Science Summit at the United Nations General Assembly (SSUNGA79) on September 26 as part of a larger panel session on the important role of SMEs in global sustainability efforts. This marks the third consecutive year that the Value Model has been included in this global forum.Valuufy's presentation will showcase how SMEs can become a more powerful force in global sustainability efforts. The session, "Empowering SMEs: Blockchain & AI for Sustainable Stakeholder Value", will also demonstrate how the ValuuCompass enables businesses of all sizes to measure, understand, and enhance value creation across all stakeholder groups.This is the third time the Value Model (which evolved into the ValuuCompass) has been presented at the SSUNGA, reinforcing the global relevance and potential of the ValuuCompass in addressing complex sustainability challenges, and offering a potential outline for how a post-SDGs could function."The ValuuCompass aims to become a global standard for sustainability by 2030, and this platform allows us to get important feedback at one of the world’s most important sustainability-focused events. We're excited to explore how blockchain and AI can help smaller businesses navigate the complex world of sustainability and position themselves as leaders in the post-SDG era," shares Kyle Barnes, CEO of Valuufy."We are honored to introduce the ValuuCompass as a powerful tool for driving sustainable business practices, especially for SMEs at this year’s Science Summit for the United Nations General Assembly."The ValuuCompass was developed by the Value Research Center at Doshisha University and is a practical tool that helps organizations measure their impact on seven key stakeholders: the organization itself, shareholders, employees, customers, partners, society, and the planet.“We know that a post-SDG world needs to act for people, planet, and prosperity and Valuufy speaks to this imperative. Its participation in SSUNGA79 builds on the discussions from previous years' presentations, which introduced the Value Model and explored its role in creating a sustainable post-SDG future,” acknowledges Heather Young, SSUNGA Japan Co-Chair.This year's focus on empowering SMEs with blockchain and AI technologies demonstrates Valuufy's commitment to making sustainable practices accessible and impactful for businesses of all sizes, and will include speakers across academia and business to explore how best to integrate the collective actions of SMEs to ensure global sustainability success.The virtual session is scheduled for Thursday, September 26, 2024, from 16:00 to 18:00 JST. There is no cost to attend, but registration is required: https://sched.co/1l8mcAbout ValuufyValuufy seeks to transform how the world understands and acts on sustainability. Founded in 2024, Valuufy, Inc is a registered Japanese startup in Kyoto, Japan, born of 10 years’ academic value research at Doshisha University and the Value Research Center. Led by an international team with expertise in value research, sustainability strategies, innovative technologies, business development, and ESG assessments, Valuufy provides a suite of products and services to promote value creation activities across stakeholders for businesses of all sizes.  Valuufy aims to set new standards in transparent, data-driven decision-making in the realm of sustainability and value creation. For more on Valuufy's products and services and its impact on shaping the future of sustainability strategies, visit www.valuufy.com.Press and Media enquiries:news@valuufy.comFollow us:linkedin.com/company/valuufy Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Sept 24, 2024 - (JCN Newswire via SeaPRwire.com) - Anticancer Agent “Tasfygo(R) Tablets 35mg” (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or RearrangementsEisai Co., Ltd. announced today that it has obtained manufacturing and marketing approval for fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor “TASFYGO® Tablets 35mg” (tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy. In Japan, it has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW), and the marketing authorization application was submitted in December 2023.This approval is based on data such as the results of a multicenter, open-label, single-arm clinical phase II trial (Study 201) conducted by Eisai in Japan and China. Study 201 enrolled 63 patients with unresectable advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements previously treated with gemcitabine-based combination chemotherapy. The primary endpoint of this study was objective response rate (ORR), and secondary endpoints included safety.1 This study achieved its primary endpoint and exceeded a prespecified tumor response threshold (15%) with statistical significance: ORR of patients treated with TASFYGO was 30.2% (90% confidence interval (CI): 20.7-41.0) as assessed by independent imaging review. Treatment-emergent adverse events (incidence of 25% or more) observed in this study were hyperphosphataemia (81.0%), palmar-plantar erythrodysaesthesia syndrome (44.4%), diarrhoea (36.5%), aspartate aminotransferase increase (31.7%), alanine aminotransferase increase (28.6%) and stomatitis (25.4%).The estimated number of patients in Japan with biliary tract cancer is approximately 22,0002,3 with approximately 25% of the five-year relative survival rate,2 making it an intractable cancer with the second worst prognosis following pancreatic cancer. Since drug therapy options are limited in comparison with other cancers, it is a disease with significant unmet medical needs. FGFR2 gene fusions or rearrangements are observed in approximately 14% of intrahepatic cholangiocarcinoma, which accounts for 15-30% of biliary tract cancers.4 FGFR genetic aberrations such as the gene fusions are known to be deeply involved in the proliferation, survival and migration of cancer cells as well as tumor angiogenesis and drug resistance. As these genetic aberrations in FGFRs have been observed in various other types of cancers as well as biliary tract cancer, there is growing interest in FGFRs as a promising target for cancer therapy. TASFYGO is thought to show tumor growth inhibition by selectively inhibiting FGFR1, 2 and 3, and blocking those signals.5,6 In non-clinical studies, the antitumor activity of TASFYGO was confirmed in cells expressing the FGFR2-fusion genes, which were identified by the National Cancer Center Japan (Headquarters: Tokyo) through large-scale genomic analysis of Japanese biliary tract cancer. The companion diagnostic test to detect FGFR2 gene fusions or rearrangements for the use of TASFYGO in biliary tract cancer, “AmoyDx® FGFR2 Break-apart FISH Probe Kit” by Nihon Stery, Inc. (Headquarters: Tokyo) was approved in August 2024.7Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals, by delivering TASFYGO as a new treatment option for biliary tract cancer with FGFR2 gene fusions or rearrangements.1. Product Information1) Brand nameTASFYGO® Tablets 35mg2) Generic nameTasurgratinib succinate3) IndicationsUnresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy4) Dosage and AdministrationThe usual adult dose of tasurgratinib is 140mg orally once daily under fasting conditions. The dose may be reduced appropriately according to the condition of the patient.About “TASFYGO® Tablets 35mg” (tasurgratinib succinate, Development Code: E7090) Discovered in-house by Eisai’s Tsukuba Research Laboratories, TASFYGO is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3. Distinct from prior known FGFR inhibitors, TASFYGO has a basic structure which lacks the dimethoxyphenyl moiety, and in a kinetic interaction analysis study, it was observed that TASFYGO demonstrates antitumor activities due to inhibition of kinase activity with a binding mode (Type V) that exhibits rapid and potent binding as well as high selectivity to FGFR. 5,6In non-clinical studies for biliary tract cancer, NIH/3T3 cells expressing FGFR2-AHCYL1, FGFR2-KCTD1, FGFR2-BICC1 or FGFR2-TXLNA as FGFR2-fusion genes, provided by the National Cancer Center Japan, were used. The antitumor activity of TASFYGO against FGFR2 gene fusion-positive cancers was confirmed in these models by evaluating its effect on anchorage-independent growth and subcutaneously transplanted tumor growth in mice.6A Phase I clinical trial is underway in Japan in patients with estrogen receptor-positive and HER2-negative breast cancer.(1) Furuse J. et al. Pivotal single-arm, phase 2 trial of tasurgratinib for patients with fibroblast growth factor receptor (FGFR)-2 gene fusion-positive cholangiocarcinoma (CCA). 2024 ASCO Gastrointestinal Cancers Symposium; Abstract No. 471. https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.3_suppl.471(2) Latest statistics, Cancer Information Service, National Cancer Center, Japan. (Japanese only)(3) The 23rd Follow-up Survey Reports for Primary Liver Cancer Cases in Japan (2014-2015), 2023. (Japanese only)(4) Arai Y. et al., Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma, Hepatology, 2014, 59, 1427-1434.(5) Miyano SW. et al., E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models, Molecular Cancer Therapeutics, 2016, 15, 2630-2639.(6) Kawano S. et al., Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion, Anticancer Research, 2024, 44, 2393-2406.(7) AmoyDx® FGFR2 Break-apart FISH Probe Kit Approved as Companion Diagnostic for Eisai’s Tasurgratinib in Japan. Available at: https://www.amoydiagnostics.com/about/press-releases/245 Last accessed: September 2024.Media Inquiries:Public Relations DepartmentEisai Co., Ltd.+81-(0)3-3817-5120 Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Sept 20, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Corporation (MC), KDDI Corporation (KDDI), and Lawson, Inc (Lawson) will launch an initiative to transform Lawson into "Next-generation Convenience Store " As the COVID-19 changed customers' lifestyles, consumption behaviors, and values, Lawson has been adapting to the “new normal” by leveraging its digital technologies. In modern society, convenience stores are essential parts of social infrastructure, contributing to steady supplies of food and daily necessities.For more than 20 years since MC invested in Lawson, MC has supported Lawson by leveraging its supply chain fields, such as raw material procurement and manufacturing logistics, and extensive overseas business networks. In response to accelerating changes in business environment, MC will enhance its collaboration with KDDI, having customer base built on telecommunications-related businesses and offering various digital services. Through the partnership, MC and KDDI will promote further transformation of Lawson.Specifically, we aim to expand "Real × Tech Convenience" by leveraging business infrastructures, AI and DX technologies of MC and KDDI. Also, we will enhance convenience stores’ roles as "Hub of refreshment in every community" by transforming into convenience stores, solving social issues that stores and communities have, through cooperation with local governments. Initiatives to transform into "Next-generation Convenience Store"1. Expansion of "Real × Tech Convenience"With the aim to implement retail-tech initiatives via digital technology to solve operational issues that retail stores are facing, such as labor shortages and food loss, two stores will be open (office space and shopping area) in “TAKANAWA GATEWAY CITY” where KDDI’s headquarter is scheduled to be relocated by the spring of 2025. The stores will be operated as an experimental lab for various retail-tech aimed at transformation of Lawson into "Next-generation Convenience Store".In the future, we will establish a Real × Tech Convenience system based on the demonstration results at the Takanawa stores and aim to expand it to other stores.Additionally, we will support and enhance Lawson's overseas expansions (including existing areas) by leveraging MC's extensive overseas business networks. Examples of demonstrations at the Takanawa store> The following functions will be introduced. Details are to be decided.FunctionContentsSmartphone Cash Register System・Frictionless payment in stores・Product recommendations through smartphonesAI Signage・Showing recommendations and campaign information based on customer attribute and membership data, with the use of AI camerasOperational Optimization・Using robots for stocking items, in-store cleaning, and product deliveryNext-Generation Remote Customer Service Platform・Setting up remote customer service booths with specialized staffs・In the early stage, we will respond to inquiries from customers regarding communications, electricity, gas, and other basic infrastructure. Eventually, we will expand our services and consider utilization of AI technology.2. Enhancing collaboration with local governments regarding disaster prevention and transportation to solve local issuesOn September 18th, 2024, MC, KDDI and Lawson signed an agreement on disaster management based on Lawson. We will work together and build up a cooperative system, for the sake of early recovery of utilities in the disaster-hit areas as well as ensuring victims feel safe and providing life support in case of a disaster. By doing so, we aim to create a secure society where people can feel comfortable and fulfilled.Furthermore, we will address local issues through the initiatives such as patrolling the areas utilizing KDDI’s Starlink network and drones to enhance community safety, and assisting transportation through on-demand mobility service ("KnowRoute" and "mobi") provided by the operating company affiliated with MC and KDDI. We aim to realize a "Lawson Town" and committed to working toward the development of an enriched community. 3. Strengthening customer contact points through the expansion of Ponta Economic ZoneSince KDDI and Loyalty Marketing, Inc. ("Loyalty Marketing ") signed a capital and business alliance agreement in 2019, MC, KDDI, and Lawson have been collaborating to expand and revitalize Ponta economic Zone through Ponta network, Loyalty Marketing’s Point program.With the goal to further revitalize Ponta Economic Zone and improve customer convenience, KDDI will renew the "au Smart Pass Premium", a package of services with coupons and contents, to "Ponta Pass" from October 2nd, 2024. Also, limited edition benefits will be offered to commemorate the launch of the service. We will continue to provide services to help customers enjoy more convenient shopping at better price at Lawson. Examples of strengthening customer contact pointsService NameContentsPonta Pass・ Weekly free and discount coupons that can be used at Lawson・ Higher Ponta point conversion rate when using "au PAY" for payment at Lawson etc.Collaboration with KDDI's online brand "povo"・ "povo Data Oasis" will start within the year, a service that customers can charge data capacity when visiting LawsonScheduled to start selling data-only eSIM at Lawson stores by the end of this fiscal yearetc.MC, KDDI and Lawson will provide new convenience store experiences to customers by expanding Real × Tech Convenience and solve local issues, such as disaster prevention and transportation, in collaboration with local governments nationwide. By doing so, we will enhance Lawson's role in modern society and transform Lawson into a "next-generation convenience store".Inquiry Recipients:Mitsubishi Corporation Public Relations Department - TEL (03)3210-2171KDDI Corporation Public Relations Department - TEL (03)6678-0690Lawson Co., Ltd. Public Relations Department - TEL (03)5435-2773 Copyright 2024 JCN Newswire via SeaPRwire.com.

LONDON, Sept 20, 2024 - (JCN Newswire via SeaPRwire.com) - Hitachi Rail's use of 5G digital signalling capabilities for urban rail, will reduce lifecycle costs, enhance actionable insights from data analytics, and future proof train networks. Replacing legacy radio technologies with 5G for critical train to ground communications is being launched on New York's Crosstown Line & Hong Kong's International Airport's Automatic People Mover.SelTrac™ CBTC is an advanced digital signalling solution, which uses train to ground telecommunications to support traffic management on a line. A technology deployed across new metros, light rail systems and is increasingly used for resignalling on existing networks. CBTC allows for higher capacities, safety and overall reliability when compared to conventional signalling systems.While CBTC technology is helping to improve performance on rail services around the world, it currently relies on the installation of legacy communication technology (radio, Wi-Fi) to enable train to ground communications. Hitachi Rail's solution with innovative 5G, removes the limitations of prior technologies and instead leverages public or private networks. The 5G solution reduces the trackside infrastructure significantly as the number of 5G Radio Access Points needed are decreased relative to the existing WiFi solution.The additional benefits of 5G are substantial, including continued high-performance connectivity in the most challenging of environments such as tunnels. Substantially increased 5G bandwidth further enables the use of advanced digital asset management solutions such as those developed by Hitachi Rail. By providing real-time reporting of the train's data, it is possible to optimize operations and maintenance of both the train and the track.Operators of 5G acquire the ability to use their expanded network capacities to deliver a range of additional services without installing new radio infrastructure, and with confidence of future 5G technology iterations (e.g. 6G) and backward compatibility. An important asset considering the 30-year lifecycle found within a radio access infrastructure.Hitachi Rail's SelTrac™ CBTC solution with the advanced 5G communication system will be deployed in two of the busiest metro networks in the world. In New York, Hitachi Rail is implementing a private 5G network for the Crosstown Line, which transports 70,000 passengers daily, and in Hong Kong, where the operator is implementing a 5G overlay network onto an existing SelTrac™ solution within the International Airport's Automatic People Mover. These projects will be one of the first to incorporate 5G connectivity for mission-critical signalling applications.Ziad Rizk, Managing Director, Urban Rail Signalling, Hitachi Rail, said: "Our first-of-its-kind 5G solution is a game changer for the urban rail market. The new 5G system plays a critical role in delivering reliable and high-capacity CBTC operations to metro operators. We offer different deployment options that best suit the customers' needs, as seen with our two references. We are proud to deliver this transformative technology to our customers and the benefits it will deliver to passengers."On 31 May, 2024, Hitachi Rail completed the acquisition of Thales' Ground Transportation Systems business (GTS), expanding the business's footprint to 24,000 colleagues across 51 countries. The acquisition has enabled Hitachi Rail to expand its product and technology portfolio, including enhancing its expertise in urban rail signalling. On 24-27 September, Hitachi Rail will exhibit a range of its urban rail products including its 5G solution at the global rail exhibition, InnoTrans in Berlin.About Hitachi RailHitachi Rail is committed to driving the sustainable mobility transition and has a clear focus on partnering with customers to rethink mobility. Its mission is to help every passenger, customer and community enjoy the benefits of more connected, seamless and sustainable transport. With revenues of over €7bn and 24,000 employees across more than 50 countries, Hitachi Rail is a trusted partner to the world's best transport organisations. The company's reach is global, but the business is local - with success built on developing local talent and investing in people and communities. Its international capabilities and expertise span every part of the urban, mainline and freight rail ecosystems – from high quality manufacturing and maintenance of rolling stock to secure digital signalling, smart operations and payment systems.Hitachi Rail, famous for Japan's iconic high speed bullet train, draws on the digital and AI expertise of Hitachi Group companies to accelerate innovation and develop new technologies. Hitachi Group is present in 140 countries with over 270,000 employees and global revenues of €54.55bn / ¥8,564 bn.For more information, visit hitachirail.com Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Sept 20, 2024 - (JCN Newswire via SeaPRwire.com) - Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, announced today the launch of a new 4K camera head1, CH-S700-08-LB, for endoscopic urology and gynecology procedures in Europe. The camera head is compatible with the VISERA ELITE III video system center for surgical endoscopy. This product is also set to be launched in Japan, Hong Kong and Singapore as soon as it is ready to comply with the regulations of each country, sequentially from September 2024. The technical development of this product was led by Sony Olympus Medical Solutions Corporation, a joint venture between Olympus and Sony Corporation.4K CAMERA HEAD OLYMPUS CH-S700-08-LBThis product provides four times the number of pixels than a conventional HD camera head, enabling observation with 4K white light images and 4K NBI (Narrow Band Imaging)2 images. It is also equipped with the BL (Blue Light)3 observation function offering versatile imaging capabilities in a single device to address diverse clinical needs. This will support high-quality diagnosis and treatment of urological diseases, including bladder cancer, by providing unprecedented endoscopic image clarity. Through the launch of this product, Olympus aims to enhance the patient care pathway of early diagnosis, minimally invasive treatment, and follow-up for non-muscle invasive bladder cancer, thereby improving the standard of care and patient outcomes.1 A camera head mainly used in endoscopic surgery in combination with an endoscope and peripheral equipment for the purpose of displaying images inside the body on a monitor. This product is also applicable to obstetric and gynecological procedures.2 NBI (Narrow band imaging) is an imaging technique for examining features such as the small blood vessels in mucosa and the surface patterns. NBI highlights tissue by illuminating it with two narrow bands (wavelengths) of light that are absorbed by the hemoglobin in blood without making use of a fluorescence dye. 3 BL (Blue Light) is an optical-digital technology that supports distinguish cancerous tissue that accumulate certain fluorophores from healthy tissue that has not. Fluorophores are then selectively deposited in a tumor and emit red fluorescence under blue excitation light. As of this release, this function is supported only in Japan. It has not yet been approved for use in Europe per the EU MDR.Background of the launchBladder cancer is one of the most common cancers that occur in the elderly population. With its high prevalence, in conjunction with its vulnerability to multiple recurrences and progression despite local therapy, this leads to a substantial health service burden globally. In particular, non-muscle invasive bladder cancer (NMIBC), which is said to account for 75% of bladder cancers, recurs in 31-78% of cases within 5 years after surgery1. In response, Olympus is focused on reducing postoperative recurrence and improving patient outcomes by enhancing cancer detection through urological endoscopy and supporting tumor resection through transurethral surgery. In September 2024, Olympus will launch the VISERA S, endoscopic visualization platform. Designed for office and ambulatory settings, which provides high-definition endoscopic images to support early detection and diagnosis of diseases. Both new product launches, the 4K CH-S700-08-LB and VISERA S, reflect Olympus' commitment to advancing urological care and improving patient outcomes by providing enhanced visibility during surgical procedures.1 Teoh, J.YC., Kamat, A.M., Black, P.C. et al. Recurrence mechanisms of non-muscle-invasive bladder cancer —a clinical perspective. Nat Rev Urol 19, 280–294 (2022). https://doi.org/10.1038/s41585-022-00578-1 Image of Olympus' solution to the entire care pathway in bladder cancerTrue 4K Image Quality and 4K NBIExclusive full 4K image sensor generates 1 billion richer colors (ITU-R BT.2020 standard for a wide color gamut) and four times finer detail than previous generations in HD, enabling the surgeon to see the crucial details of the superficial layer of the mucosa that are important in urologic endoscopic surgery. NBI is a unique optical-digital technology that enhances visualization of mucosal structure and capillary patterns in the bladder using wavelengths that are highly absorbed by hemoglobin. It provides higher contrast and reveals significantly more tissue detail than WLI. This supports more precise lesion detection and resection.Unified Visualization that relevant for endourology proceduresWhile a dedicated system was conventionally required to perform BL observation, this product enables white light observation, NBI observation, and BL observation with a single camera head, eliminating the need for system switches. The BL offers brighter backgrounds with improved color tone and clear contrast in HD for better visibility, contributing to more effective resections. It meets different observation needs depending on the case and supports more efficient operation of the equipment at medical institutions.Effortless Usability and ErgonomicsOne-touch autofocus supports precise endoscopic visualization and can be activated on the camera head body. Fine texture details are clearly visible at the touch of a button, minimizing distractions and enabling continuous focus on the procedure.The product is manufactured by Olympus Medical Systems Corp.About OlympusAt Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global X account: @Olympus_CorpMedia contact:Mail: Global-Public_Relations@olympus.com Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com   Copyright 2024 JCN Newswire via SeaPRwire.com.